fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Positive CHMP opinion for Xtandi (enzaltamide) in additional recurrent early prostate cancer treatment setting – Astellas

Written by | 30 Mar 2024

Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Xtandi (enzalutamide)… read more.

MHRA approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by | 23 Dec 2023

Veoza (Veozah in the US), also known as fezolinetant, from Astellas, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval in… read more.

European Commission approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by | 18 Dec 2023

Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS)… read more.

Padcev and Keytruda significantly improve overall survival and progression-free survival in previously untreated advanced bladder cancer in pivotal phase III EV-302 trial – Seagen + Astellas

Written by | 5 Oct 2023

Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the Phase III EV-302 clinical trial (also known as KEYNOTE-A39) for Padcev (enfortumab vedotin-ejfv) in combination with… read more.

Xtandi accepted for EMA review for earlier type of prostate cancer – Astellas

Written by | 21 Sep 2023

Astellas announced that the European Medicines Agency (EMA) has validated its Type II variation for Xtandi (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC… read more.

FDA grants priority review for Xtandi in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence – Astellas + Pfizer

Written by | 1 Sep 2023

Pfizer Inc. and Astellas Pharma Inc. announced that the FDA has accepted and granted Priority Review for the companies’ supplemental New Drug Application (sNDA) for Xtandi (enzalutamide) for… read more.

FDA approves Izervay for geographic atrophy – Astellas/Iveric

Written by | 12 Aug 2023

Astellas Pharma Inc announced the FDA approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4,… read more.

Phase IIIb trial of fezolinetant shows positive topline results for treatment of vasomotor symptoms – due to menopause – Astellas

Written by | 17 Jul 2023

Astellas Pharma Inc. announced positive topline results from the Phase IIIb DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.